A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias.

In this week’s edition of InnovationRx, we look at the impact of Medicaid cuts, a $400 million obesity bet, a study of bias ...

Relief is coming for more than 5 million Medicare beneficiaries who rely on expensive prescription medications.

People who have tried other methods to lose weight have found results from obesity drugs that ‘feel like magic.’ ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

As discussions unfold, Kennedy seeks to balance drug accessibility with concerns about the long-term costs of providing GLP-1 ...

In a New York Times column this week, the Pennsylvania Democrat shared his experience taking Mounjaro while advocating for ...

Fetterman appealed to President Trump and Health and Human Services Secretary Robert F. Kennedy Jr. personally.

Sen. John Fetterman (D-Pa.) on Wednesday called on the Trump administration to back a Biden-era rule that would expand access ...

The Trump administration announced Friday it will not move forward with plans to cover popular weight-loss drugs under ...

Prior to Friday's decision, the Obesity Action Coalition along with 80 other organizations sent a letter to HHS Secretary ...

In November, Mr. Biden set out to change that with a new rule that would drastically expand access to this type of medication ...